New Support for Ovarian Suppression with Endocrine Therapy in Premenopausal Breast Cancer

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer.

Source: CancerNetwork - September 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news